Insider Purchases: Inside the Buy
Tag: InsiderBuying
Proto Labs (PRLB): The CEO Bought Shares. Should You?
The CEO of Proto Labs just invested in his own company — but it’s not just him. Wall Street giants are in, revenue’s at record levels, and PRLB might be building toward a breakout. Should you 3D-print it into your portfolio?
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
EPD: Enterprise Products Partners Is Boring—But It Pays to Be Boring
Enterprise Products Partners (EPD) might not make headlines, but it makes money. With insiders buying big, a solid 7% dividend, and decades of steady growth, this is one midstream stock that flows cash — not drama.
Insiders Bought "MicroStrategy" Shares at $90. You’re Paying $394.66. Should You?
MSTR insiders are buying, but not the stock you think. They bought STRC at $90 — while MSTR trades near $400. What gives? We break down the numbers, the Bitcoin twist, and what might be worth nibbling on.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Simmons Bank: Insider Buys, 116 Years of Dividends, and a Footlong Public Offering
Simmons Bank has paid dividends for over a century—and insiders just went on a buying spree. 📉 Stock’s dipped, 🔍 valuation isn’t screaming cheap, but with improving net income and institutional support, SFNC might be worth a second look. If not exciting, at least it’s… dependable?
Can Elevance Reach Higher Elevations? The CEO Thinks So
📉 After falling nearly 50% from its highs, Elevance Health just got a $2.4M vote of confidence from its CEO. Is this the cure—or just another symptom? 🏥 Dive into the numbers, the risks, and the potential rewards. And yes, there will be icons. 📊💊📈
Helen of Troy (HELE) — Insider Buys, CFOs Turned CEOs, and a Falling Knife You Might Want to Catch (Carefully)
The CEO and CFO of Helen of Troy just bought shares as the stock plunges 90%. Are we looking at a tragic tale, or a comeback for the ages? We dig into the numbers, leadership shuffle, and Wall Street signals—with humor and historical flair.
Healthpeak Properties (DOC): Insiders Are Buying—Should You?
📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.
PVH: Fashion. Fundamentals. CEO Buying. Doesn't the $500M Share Buyback Scream Deep Value?
CEO Stefan Larsson just bought $1M worth of PVH stock—and he’s not alone. With iconic brands like Calvin Klein and Tommy Hilfiger, institutional support over 100%, and a massive share buyback underway, PVH may be a classic turnaround play. But is it fashionably early… or just fashionably risky?